1-(5-TERT-BUTYL-2-PHENYL-2H-PYRAZOL-3-YL)-3-[2-FLUORO-4-(1-METHYL-2-OXO-2,3-DIHYDRO-1H-IMIDAZO[4,5-B]PYRIDIN-7-YLOXY)-PHENYL]-UREA AND RELATED COMPOUNDS AND THEIR USE IN THERAPY
CANCER RESEARCH TECHNOLOGY LIMITED;INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (THE)
发明人:
Caroline Joy SPRINGER,Ion NICULESCU-DUVAZ,Richard MARAIS,Dan NICULESCU-DUVAZ,Alfonso ZAMBON,Delphine MENARD
申请号：
US15254103
公开号：
US20170079963A1
申请日:
2016.09.01
申请国别(地区):
US
年份:
2017
代理人:
摘要：
The present invention pertains generally to the field of therapeutic compounds, and more specifically to certain compounds of the following formula (for convenience, collectively referred to herein as “IP compounds”), which, inter alia, are useful in the treatment of cancer, e.g., cancer characterised by (e.g., driven by) mutant RAS (“mutant RAS cancer”). The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions in the treatment of cancer, e.g., mutant RAS cancer.
